REMARKS

Following the entry of the amendments in the Response mailed November 18, 2005, Claims 1-3, 5-8, and 16-23 are pending in the application.

In the Final Office Action dated February 6, 2006, the Examiner made a number of rejections, some new, and some maintained. For clarity, the objections and rejections at issue are set forth by number in the order they are herein addressed:

- Claims 1 and 16-22 are newly rejected under 35 USC 112, second paragraph, as being indefinite;
- Claims 16-17 remain rejected under 35 USC 102(a) as anticipated by Martey et al.
 (CAPLUS abstract 1998: 529836, 1998);
- Claims 1-3, 5, 6, 16, and 17, remain rejected under 35 USC 103(a) as obvious over Heindel (Bioconjugate Chem., 1994) in view of Diener (US Patent No. 4,415,552) and further in view of either Akanuma et al. (J. Biochem., 1978) or Martey et al. (CAPLUS abstract 1998: 529836, 1998);
- Claims 3, 5, 16, 20, and 23 remain rejected under 35 USC 103(a) as obvious over Heindel (Bioconjugate Chem., 1994) in view of Weinshenker (US Patent No. 5,068,227) and further in view of either Akanuma et al. (J. Biochem., 1978) or Martey et al. (CAPLUS abstract 1998: 529836, 1998);
- 5. Claims 3, 5, 16, 21 and 23 remain rejected under 35 USC 103(a) as obvious over Heindel (Bioconjugate Chem., 1994) in view of Elson (US Patent No. 5,888,988) and further in view of either Akanuma et al. (J. Biochem., 1978) or Martey et al. (CAPLUS abstract 1998: 529836, 1998);
- 6. Claims 3, 5, 8, 16, 19, and 23 remain rejected under 35 USC 103(a) as obvious over Heindel (Bioconjugate Chem., 1994) in view of Hattori et a. (J. Agric. Food Chem., 1995) and further in view of either Akanuma et al. (J. Biochem., 1978) or Martey et al. (CAPLUS abstract 1998: 529836, 1998); and
- 7. Claims 3, 5, 7, 16, 18, 22, and 23 remain rejected under 35 USC 103(a) as obvious over Heindel (Bioconjugate Chem., 1994) in view of Mill (US Patent No.

Response to Office Action Page 3 of 6

4,003,972) and further in view of Streitwieser et al. (Introduction to Organic Chemistry, 1976).

The previous rejections in the Office Action dated June 6, 2005 were not maintained, and are thus presumed overcome in the preceding Response to that Office Action.

- 1. Claims 1, 2, and 6-22 are rejected under 35 USC 112, second paragraph, as being indefinite; and
- 2. Claims 1 and 2 are rejected under 35 USC 112, first paragraph, as failing to comply with the enablement requirement.

The Applicants believe that the claims as pending are allowable, for all of the reasons presented in the previous Response filed on November 18, 2005. However, in Response to the Final Office Action, the Applicants have filed a continuing patent application on April 21, 2006. The continuing patent application was filed for the purpose of furthering the Applicants' business goals and expediting the patent application process in a manner consistent with the PTO's Patent Business Goals (PBG), ¹ and without waiving the right to prosecute in the future the pending (or similar) claims of the present application in another application, and without acquiescing to any of the Examiner's arguments. A copy of the filing papers, along with the first page of the continuing patent application, are attached to this Response as Exhibit 1.

¹ 65 Fed. Reg. 54603 (September 8, 2000).

CONCLUSION

If the Examiner has any questions or requires any additional information, the Examiner is invited and encouraged to contact Applicants' undersigned representative at the telephone number listed below.

Respectfully submitted,

Jaen Andrews

Registration No. 35,051 Attorney for Applicants

COMPETITIVE TECHNOLOGIES, INC. 1960 Bronson Road Fairfield, CT 06824

Telephone:

(203) 255-6044

Fax:

(203) 254-1102

EXHIBIT 1

Customer Copy 2000 Laber 11-5 May 2000 INSURANCE COVERAGE LIMITS SERVICE GUARANTEE AND SEE REVERSE SIDE FOR Commissioner for Patente Alexandria, VA P.O. BOX 1450 EXPRESS TO ADDRESSEE POST OFFICE

CTT

BEST AVAILABLE COPY

EX 1-1

RECEIVED CENTRAL FAX CENTER

APR 2 8 2006

PAGE 08

	Ap	PTO/SB/05 (04-05) proved for use through 07/31/2006, OMB 0851-0032			
Under the Paperwork Reduction Act of 1995, no persons are required to re-	IIS Drings and Tree	AMAN ORAA IIR DEDARTHERDE ACAAAAA			
UTILITY	Attorney Docket No.	LEH-35-98 CIP			
PATENT APPLICATION	First Inventor	Ned Heindel			
TRANSMITTAL	Title	Lactones of Carboxyllo Acid			
(Only for new nonprovisional applications under 37 CFR 1.53(b))	Express Mail Lebel No.	EF026156711US			
APPLICATION ELEMENTS See MPEP chapter 800 concerning utility patent application contents.	ADDRESS TO:	Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450			
1. Fee Transmittel Form (e.g., PTO/SB/17)	ACCOMPAN	IYING APPLICATION PARTS			
(Submit an original and a duplicate for fee processing) 2. Applicant claims email entity status. See 37 CFR 1,27.		apers (cover sheet & document(s))			
3. Specification [Total Pages 50] Both the claims and ebetract must start on a new page	Name of Assignee				
(For Information on the preferred errangement, see MPEP 608.01(4)) 4.	·				
5. Oath or Declaration [Total Sheets 3] a. 7 Newly executed (original or copy) b. A copy from a prior application (37 CFR 1.63(d))	10. 37 CFR 3.73(b) (when there	s an assignee) Power of Attorney			
(for continuettan/divisional with Box 18 completed) i. DELETION OF INVENTOR(S)	11. English Trans	lation Document (if applicable)			
Signed statement stached deleting inventor(s) name in the prior application, see 37 CFR 1.83(d)(2) and 1.33(b).	12. Information D	isclosure Statement (PTO/SB/08 or PTO-1442) s of citations attached			
6. Application Data Sheet. See 37 CFR 1.76	13. Preliminary A	mandmant			
7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) Landscape Table on CD	14. Return Receipt Postcard (MPEP 503) (Should be specifically Itemized)				
B. Nucleotide and/or Amino Acid Sequence Submission (if applicable, Items a. – c. are required) a Computer Readable Form (CRF)	15. Certified Copy of Priority Document(s) (if foreign priority is claimed) 16. Nonpublication Request under 35 U.S.C. 122(b)(2)(B)(l). Applicant must attach form PTO/SB/35 or equivalent.				
b. Specification Sequence Listing on: [. CD-ROM or CD-R (2 copies); or					
ii. Paper	17. Other:				
c. Statements verifying identity of above copies					
18. If a CONTINUING APPLICATION, check appropriate box, and supp specification following the title, or in an Application Data Sheet under 37	ry the requisite information CFR 1.76:	n below and in the first sentence of the			
		ior application No.: 09/493,891			
Prior application information: Examiner Majer Leich C. Art Unit: 1623					
19. CORRESPONDENCE ADDRESS					
The eddress associated with Customer Number.		OR Correspondence address below			
Name 3334/					
Address					
City State		Zip Code			
Country Telephone		Email			
Signature Au Hvorrus	Dat	7/2 1/2000			
(Prim/Type) Jeen Andrews		Registration No. (Attorney/Agent) 35,051			

This collection of information is required by 37 CFR 1.53(b). The information is required to obtain or retain a benefit by the public which is to fite (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the includual case. Any comments on this amount of time you require to complete this form endors suggestions for reducing this burden, should be sent to the Chief Information Officer. U.S. Petern and Trademark Office. U.S. Department of Commence, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need essistance in completing the form, call 1-800-PTO-9199 and select option 2.

PAGE 8/13 * RCVD AT 4/28/2006 10:42:25 AM [Eastern Daylight Time] * SVR:USPTO-EFXRF-3/11 * DNIS:2738300 * CSID:2032551536 * DURATION (mm-ss):06-34

RECEIVED CENTRAL FAX CENTER

APR 2 8 2006

PAGE 10

PTO/SB/01 (10-05)

APR Z 0 ZUUU

Approved for use through 07/31/2005, OMB 0851-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Attorney Docket LEH-35-98 CIP **DECLARATION FOR UTILITY OR** Number First Named Inventor DESIGN Ned Heindel PATENT APPLICATION COMPLETE IF KNOWN (37 CFR 1.63) Application Number Filing Date Declaration Declaration 4/21/2008 Submitted OP Submitted after initial Art Unit With Initial Filing (surcharge Flling (37 CFR 1.16 (e)) Examiner Name required) I hereby declare that: Each Inventor's residence, mailing address, and citizenship are as stated below next to their name. I believe the inventor(s) named below to be the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled: actones of Carboxylic Acid Polysaccharides and Methods for Forming Conjugates Thereof. (Title of the Invention) the specification of which is attached hereto OR was filed on (MM/DD/YYYY) as United States Application Number or PCT International Application Number and was amended on (MM/DD/YYYY) (if applicable). thereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application. I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent, inventor's or plant bresder's rights certificate(s), or any PCT international application having a filing date before that of the application on which priority is claimed. **Prior Foreign Application** Foreign Filing Date Priority Certified Copy Attached? Number(s) Country (MM/DD/YYYY) Not Claimed YES Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.83. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 21 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Afty comments on the amount of time you require to complete this form end/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance completing the form, call 1-800-PTO-9199 and select option 2.

5x 1-4

PAGE 10/13 * RCVD AT 4/28/2006 10:42:25 AM [Eastern Daylight Time] * SVR:USPTO-EFXRF-3/11 * DNIS:2738300 * CSID:2032551536 * DURATION (mm-ss):06-34

PTQ/SB/01 (10-05) Approved for use through 07/31/2006, OMB 0651-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a velid OMB control number. **DECLARATION** — Utility or Design Patent Application Direct all QR The address Correspondence correspondence to: associated with address below 33347 Customer Number: PATENT TRADEMARK OFFICE Address City State ZIP Country Telephone Email WARNING: Petitioner/applicant is cautioned to avoid submitting personal, information in documents filed in a patent application that may contribute to identity theft. Personal Information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 16 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. NAME OF SOLE OR FIRST INVENTOR: A petition has been filed for this unsigned inventor Given Name (first and middle [if any]) Family Name or Surname Ned D. Heindel Inventor's Signature Date Residence: City State Country Citizenship PΑ Easton Malling Address 200 Hexenkopf Road City State Zip Country Ession 18042 Additional invontors or a legal representative are being named on the 1 supplemental sheet(s) PTO/SB/02A or 02LR attached hereto

(Page 2 of 2)

EX 1-5

PAGE 11/13 * RCVD AT 4/28/2006 10:42:25 AM [Eastern Daylight Time] * SVR:USPTO-EFXRF-3/11 * DNIS:2738300 * CSID:2032551536 * DURATION (mm-ss):06-34

Under the Penerwork Reduction Act of 1995, no perso	ns ere required to re	U.S. Patent a	Approved for use thro and Trademark Office; U.S. of information unless it por	PTO/SB/02A (09-04) ough 07/31/2006. OMB 0651-0032 DEPARTMENT OF COMMERCE tgins a valid QMB control number.	
DECLARATION			INVENTOR(S)	Page 1 of 1	
Name of Additional Joint Inventor, if an	y:	A petition	A petition has been filled for this unsigned inventor		
	Given Name (first and middle (if any)) Family Name or Sumame		Sumame		
Wallace D.	· · · · · · · · · · · · · · · · · · ·	Longton			
Inventor's Signature				Date	
Cansie	PA	USA		US	
Residence: City	State	Cou	intry	Citizenship	
7 Derbyshire Drive Mailing Address					
Carlisle	PA		17013	USA	
City	State	·	Zip	Country	
Name of Additional Joint Inventor, if an	y: .	A petition	has been filed for this u	nsigned inventor	
Given Name (first and middle (if any)) Family Name or Surname		umame			
Christine		Martey			
Inventor's Signature Date				Date	
Somerset	L/J		USA	us	
Residence: City	State		Country	Citizenship	
132 Hempstead Drive					
Malling Address					
Somerset	. מא		08873	USA	
City	State		Zip	Country	
Name of Additional Joint Inventor, If any: A petition has been filed for this unsigned inventor					
Given Name (first and middle (if any)) Family Name or Sumame		ımame			
Robert					
Inventor's Signature				Date	
Laurelidals	PA		UŞA	³⁶ us	
Residence: City	State		Country	Citizenship	
1804 Eizebeth Avenue					
Mailing Address					
Laurelidale City	PA State		19605 Žip	USA Country	

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.83. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 21 minutes to complete, including gathering, preparing, and submitting the completed application for the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petert and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1460.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

EX 1-6

PAGE 12/13 * RCVD AT 4/28/2006 10:42:25 AM [Eastern Daylight Time] * SVR:USPTO-EFXRF-3/11 * DNIS:2738300 * CSID:2032551536 * DURATION (mm-ss):06-34

Express Mail Label No. EF026156711US

U.S. Patent Application Docket No. 35-98 CIP

LACTONES OF CARBOXYLIC ACID POLYSACCHARIDES AND METHODS FOR FORMING CONJUGATES THEREOF

This application is a continuation-in-part of co-pending US Patent Application Serial No. 09/493,891, filed January 28, 2000, which is incorporated herein in its entirety, and claims the benefit of co-pending US Provisional Patent Application Serial No. 60/674,343, filed April 22, 2005, which is incorporated herein in its entirety.

FIELD OF THE INVENTION

The present invention relates to sustained release drug and other compound conjugates, and in particular to carboxymethylcellulose-drug conjugates, and to related carboxylic acid polysaccharide-bioactive compound conjugates.

BACKGROUND OF THE INVENTION

The treatment of many diseases often involves the administration of drugs. Such drugs may be biocides, as for example anti-bacterial or antiviral drugs, or they may supply missing metabolic intermediates or end-products, or they may inhibit or stimulate a normal metabolic pathway in the body. Not infrequently, such drugs have a limited or local target, and are toxic or have other untoward side effects when active outside the limited or local target. However, most drugs are delivered systemically, or non-specifically, as for example orally (by pills and liquids), by injection, and by transfusion, and reach approximately the same concentration throughout the body. On the other hand, it is difficult to reach certain targets with systemically delivered drugs; as an example, the blood-brain barrier prevents many circulating drugs from reaching the brain. Moreover, once administered, drugs are typically metabolized by the body to an inactive form, and/or excreted, thus exhibiting a short lifetime in the body and requiring frequent doses to maintain an effective concentration at the targeted site.

Therefore, it would be desirable to develop drug delivery systems that could deliver drugs directly to the desired target, or very nearby. This would result in the rapeutically effective concentrations at the desired target, but with lower concentrations elsewhere in the

, Ex 1-7

4. OTHER FEE(S)

RECEIVED CENTRAL FAX CENTER

PAGE 09

APR 2 8 2006

PTO/SB/17 (01-06)

Approved for use through 07/31/2006. OMB 0851-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid QMB control number Complete if Known Fees pursuent to the Consolidated Appropriations Act, 2005 (H.R. 4818). **Application Number** TRANSMIT 4/21/2006 Fillno Date For FY 2006 Ned Heindel First Named Inventor Examiner Name Applicant claims small entity status. See 37 CFR 1.27 Art Unit TOTAL AMOUNT OF PAYMENT 880 LEH-35-98 CIP Attorney Docket No. METHOD OF PAYMENT (check all that apply) Check Credit Card Money Order Other (please identify): None Deposit Account Name Competitive Technologies 032634 Inc. X Deposit Account Deposit Account Number For the above-identified deposit account, the Director is hereby authorized to: (check all that apply) X Charge fee(s) indicated below Charge fee(s) indicated below, except for the filing fee Charge any additional fee(s) or underpayments of fee(s) Credit any overpayments X Under 37 CFR 1.16 and 1.17

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card Information and authorization on PTO-2038. FEE CALCULATION (All the fees below are due upon filing or may be subject to a surcharge.) 1. BASIC FILING, SEARCH, AND EXAMINATION FEES SEARCH FEES **FILING FEES EXAMINATION FEES Small Entity** Small Entity Small Entity **Application Type** Fee (\$) Fee (\$) Fees Paid (\$) Fee (\$) Fee (\$) Fee (\$) Fee (\$) \$500 300 Utility 150 500 250 200 100 Design 200 100 100 130 50 65 200 300-Plant 100 150 160 80 300 500. 600 Reissue 150 250 300 **Provisional** 200 0 100 0 O 0 2. EXCESS CLAIM FEES Small Entity Fee (\$) Fee Description Fee (5) 50 Each claim over 20 (including Reissues) 25 200 100 Each independent claim over 3 (including Reissues) Multiple dependent claims 360 180 **Total Claims** Extra Claims Fee Paid (\$) Multiple Dependent Claims Fee (3) ___ - 20 or HP = ٥ Fee (\$) Fee Paid (\$) HP = highest number of total claims paid for, if greater than 20. 180 \$180 Indep, Claims Fee (\$) Extra Claims Fee Paid (\$) 100 - 3 or HP = \$200 2 HP = highest number of independent claims paid for, if greater than 3. **APPLICATION SIZE FEE** If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets Number of each additional 50 or fraction thereof Fee Paid (\$) Total Sheets Extra Sheets Feo (\$)

Non-Eng	dish Specification, \$130 fee (no small	entity discount)	. Pags Paid (5)
Other (e.	g., late filing surcharge):		
SUBMITTED BY			
Signature	Jun Andrews	Registration No. 35,051 (Attorney/Agent)	Telephone 203-255-6044
Name (Print/Tve	Jaen Andrews		Date 4/01/2006

(round up to a whole number) x

This collection of information is required by 37 CFR 1.138. The information is required to obtain or retain a bernefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the includings case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer. U.S. Patient and Trademark Office. U.S. Department of Commence. P.O. Box 1450. Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Petents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Fees Paid (\$)